RecombinantRabMAb

Recombinant HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)

Submit a review Submit a question References (5)
Western blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
  • Dot Blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
  • HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • HRP Rabbit monoclonal [EPR1899(2)] to JAK1 (phospho Y1022 + Y1023)
  • Suitable for: Dot blot, WB
  • Reacts with: Human
  • Conjugation: HRP

Overview

  • Product name

    HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)]
    See all JAK1 primary antibodies

  • Description

    HRP Rabbit monoclonal [EPR1899(2)] to JAK1 (phospho Y1022 + Y1023)

  • Host species

    Rabbit

  • Conjugation

    HRP

  • Tested applications

    Suitable for: Dot blot, WBmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human JAK1 aa 1000-1100 (phospho Y1022 + Y1023). The exact sequence is proprietary.
    Database link: P23458

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab215338 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Dot blot 1/1000.
WB 1/1000. Detects a band of approximately 133 kDa (predicted molecular weight: 133 kDa).

Target

  • Function

    Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.

  • Tissue specificity

    Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.

  • Domain

    Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
    The FERM domain mediates interaction with JAKMIP1.

  • Cellular localization

    Endomembrane system. Wholly intracellular, possibly membrane associated.
  • Information by UniProt

  • Database links

    • Alternative names

      • JAK 1 antibody
      • JAK 1A antibody
      • JAK 1B antibody
      • JAK-1 antibody
      • JAK1 antibody
      • JAK1_HUMAN antibody
      • JAK1A antibody
      • JAK1B antibody
      • Janus kinase 1 (a protein tyrosine kinase) antibody
      • Janus kinase 1 antibody
      • JTK3 antibody
      • Tyrosine protein kinase JAK 1 antibody
      • Tyrosine protein kinase JAK1 antibody
      • Tyrosine-protein kinase JAK1 antibody
      see all

    Images

    • Western blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
      Western blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
      All lanes : HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338) at 1/1000 dilution

      Lane 1 : Untreated Ramos cells
      Lanes 2-3 : Ramos cells treated with pervanadateat at 1mM for 30min

      Predicted band size: 133 kDa
      Observed band size: 133 kDa


      Exposure time: 5 seconds
    • Dot Blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
      Dot Blot - HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)

      Dot blot analysis of JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (HRP) (ab215338) at 1/1000 dilution.
      Lane 1: JAK1 (phospho Y1022) phospho peptide.
      Lane 2: JAK1 (phospho Y1023) phospho peptide.
      Lane 3: JAK1 (phospho Y1022 + Y1023) phospho peptide.
      Lane 4: JAK1 non phospho peptide.

      Blocking and diluting buffer and concentration: 5% NFDM/TBST. Exposure time: 3 minutes.

    • HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)
      HRP Anti-JAK1 (phospho Y1022 + Y1023) antibody [EPR1899(2)] (ab215338)

    References (5)

    Publishing research using ab215338? Please let us know so that we can cite the reference in this datasheet.

    ab215338 has been referenced in 5 publications.

    • Shi Q  et al. microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF. Iran J Basic Med Sci 22:541-546 (2019). PubMed: 31217935
    • Gong W  et al. Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a. J Cell Biochem 120:836-847 (2019). PubMed: 30125989
    • Cui J  et al. WITHDRAWN: Skullcapflavone I has a potent anti-pancreatic cancer activity by targeting miR-23a. Life Sci N/A:N/A (2019). PubMed: 31085241
    • Li Y  et al. Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway. BMC Cancer 18:1230 (2018). PubMed: 30526546
    • Yin D  et al. Pro-Angiogenic Role of LncRNA HULC in Microvascular Endothelial Cells via Sequestrating miR-124. Cell Physiol Biochem 50:2188-2202 (2018). PubMed: 30415256

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab215338.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com